相关实验视频

Updated: Jul 29, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

与二硫化相关的分子亚型和预后模型,以优化转移性骨肉瘤患者的药物治疗

Xiaoping Wang^1,2, Chao Xie¹, Lijun Lin¹

¹Department of Joint and Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

|December 14, 2024

概括

不硫化,一种新的细胞死亡形式,为骨髓瘤 (OS) 提供了预后见解. 识别INF2和MEGF10等关键基因有助于预测转移,并开发有针对性的疗法,以改善患者的存活率.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
遗传学遗传学是一种遗传学.

背景情况:

不硫化是新兴的细胞死亡途径,与癌症的进展和治疗反应有关.
了解与脱硫素相关的基因 (DiRGs) 对于改善骨髓瘤 (OS) 患者的治疗结果至关重要.

研究的目的:

确定DiRG并建立骨髓瘤 (OS) 的预后模型.
探索二硫化在OS免疫微环境和转移中的作用.
确定潜在的治疗点和用于OS治疗的药物.

主要方法:

使用了来自OS的TARGET和GEO数据库的基因表达数据和临床信息.
使用无监督聚类来识别DiRG分子子组.
开发了一个基于五个DiRG的预后模型,并分析了免疫透和药物向相互作用.

主要成果:

在OS中,两个不同的DiRG分子子组显示了瘤异质性和免疫透的差异.
一个五个DiRG的预后模型显示了对OS患者生存的显著预测能力 (AUC 0.69-0.85).
确定INF2和MEGF10是转移的关键预测因素,并确定了潜在的候选药物.

结论:

不硫化症在OS中起着重要作用,影响预后和免疫状态.
开发的预后模型和已识别的DiRG (INF2,MEGF10) 可以帮助预测OS转移.
针对特定的DiRG可能为骨髓瘤提供新的治疗策略.

关键词:

硫化物脱硫症 (disulfidptosis) 是一种脱硫症.免疫疗法免疫疗法分子子类型分子子类型骨质肉瘤是骨质肉瘤的一种疾病.瘤免疫微环境是一个微环境.

更多相关视频

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...